The prostate is a walnut-sized gland that produces seminal fluid. It wraps around the urethra just below the bladder, which explains why prostate conditions frequently cause urinary symptoms. Three conditions account for most prostate pathology: prostatitis (inflammation, often from infection), benign prostatic hyperplasia (BPH, non-cancerous enlargement), and prostate cancer. All three become more common with age, though they differ substantially in clinical significance and treatment approach.

Benign Prostatic Hyperplasia (BPH)

BPH is almost universal in older men, autopsy studies show histological evidence of BPH in approximately 50% of men in their 50s, rising to 80% by their 80s. Most men with histological BPH do not develop significant symptoms, but as many as half of men over 70 have clinically significant lower urinary tract symptoms (LUTS) from prostate enlargement.

BPH symptoms arise because the enlarged prostate compresses the urethra and reduces urinary flow. Classic symptoms include urinary urgency (sudden strong urge to urinate), frequency (urinating more than 8 times per day), weak stream, intermittency, sensation of incomplete emptying, and nocturia (waking at night to urinate). These collectively constitute the lower urinary tract symptom complex.

Symptom severity is assessed using the International Prostate Symptom Score (IPSS), an 8-question validated questionnaire. Scores of 0-7 indicate mild symptoms that typically require only watchful waiting. Scores of 8-19 indicate moderate symptoms where lifestyle changes and medication are appropriate. Scores above 20 indicate severe symptoms where more aggressive treatment is considered.

Treatment options by severity:

Lifestyle modifications (mild symptoms): Limiting fluid intake in the hours before bed, reducing caffeine and alcohol, double voiding (waiting after initial urination to void again), and timed voiding.

Alpha-blockers (moderate symptoms): Tamsulosin, silodosin, and alfuzosin relax smooth muscle in the prostate and bladder neck, improving urinary flow. They work quickly, often within 48 hours, but do not shrink the prostate.

5-alpha reductase inhibitors (moderate-severe symptoms, enlarged prostate confirmed): Finasteride and dutasteride reduce prostate volume by blocking DHT-mediated prostate growth. They take 3-6 months to produce maximum effect and work best in men with significantly enlarged prostates.

Tadalafil 5 mg daily: As covered in Daily Tadalafil: What the Evidence Shows, this is FDA-approved for BPH and provides symptom relief comparable to alpha-blockers through a different mechanism. Useful in men who also have ED.

Surgical options: TURP (transurethral resection of the prostate) is the reference standard surgical procedure. Newer minimally invasive procedures including Urolift (mechanical lifting of prostate tissue) and Rezum (water vapor therapy) offer alternatives with shorter recovery times.

Prostatitis

Prostatitis, prostate inflammation, most commonly from bacterial infection, is the most common urological diagnosis in men under 50. It presents as pelvic pain, urinary symptoms, pain with ejaculation, and sometimes fever and systemic illness in acute bacterial cases.

Four categories of prostatitis exist:

  • Category I: Acute bacterial prostatitis, fever, severe symptoms, requires urgent antibiotics
  • Category II: Chronic bacterial prostatitis, recurrent urinary infections, less acute symptoms
  • Category III: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), most common type, no confirmed bacterial infection, poorly understood
  • Category IV: Asymptomatic inflammatory prostatitis, found incidentally on biopsy

Category III (CP/CPPS) accounts for 90-95% of prostatitis diagnoses and is the most challenging to treat. Antibiotics are often prescribed but are not clearly effective in the absence of documented bacterial infection. Multimodal management including alpha-blockers, pelvic floor physical therapy, dietary modifications, and psychological support produces better outcomes than antibiotic-only treatment in most trials.

Prostate Cancer Basics

Prostate cancer is the second most commonly diagnosed cancer in American men (after skin cancer) and the second most common cause of cancer death. The American Cancer Society estimates approximately 300,000 new cases and 35,000 deaths annually.

Prostate cancer is predominantly a disease of older men, 60% of cases occur in men over 65. It is rare before 40. African American men have a higher incidence and mortality than other racial groups and may benefit from earlier screening.

Most prostate cancers are slow-growing and clinically insignificant, this is the central challenge in screening and treatment decision-making. Autopsy studies consistently find that 30-40% of men over 50 who die of other causes have histological prostate cancer they never knew about. Identifying which cancers will cause harm versus which can be safely monitored requires ongoing clinical judgment.

PSA screening, its interpretation, and the screening debate are covered separately in PSA Testing: Who Needs It and What the Numbers Mean.

For information on how testosterone and prostate cancer interact, particularly relevant for men considering TRT, see TRT Side Effects: What the Research Actually Shows.